2023 Guidance and Q3 Earnings

General Medicines: anticipate low to mid single-digit growth in 2023 General Medicines -2% in line with expectations Trelegy +23%: most prescribed SITT worldwide: on track to deliver over £2bn in 2023 Post-pandemic recovery: EU and International antibiotic market recovering RAR impact: Q3 growth negatively impacted by 6 percentage points Trelegy: growth opportunity remains for SITT class in US Single inhaler triple therapy is the fastest-growing maintenance therapy for COPD & asthma² Trelegy is the fastest-growing triple therapy for COPD & asthma² Trelegy is the market leader in the COPD & asthma triple class² Trelegy Q3 2023 sales since launch 600 M 500 M 400 M 300 M 200 M 100 M 0 M Q3 2018 Q3 2019 Q3 2020 Q3 2021 Q3 2022 Q3 2023 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% COPD patient class share in US² Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Apr-23 39% 38% 28% 10% 3% GSK 18 Absolute values at AER; changes at CER, unless stated otherwise 1. IQVIA MIDASⓇ monthly data, since launch up to (and including) Aug 2023, reflecting estimates of real-world activity 2. Information licensed from IQVIA: National Custom Patient Report utilizing LRx, Dx data assets for the period Jun 2022 to August 2022 reflecting estimates of real-world activity May-23 Jun-23 Jul-23 Aug-23 ICS/LABA ICS MITT SITT Triple

View entire presentation